ChronoScale Holdings Corporation
CHRNChronoScale Holdings Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is already 17 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (17 weeks in). Underneath, the last four quarters read mixed. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
ChronoScale Holdings Corporation trades at $24.4, in a confirmed uptrend and 17 weeks into that stage. That is +107.9% against its own 200-day average. It sits at 91% of a 52-week range of $3 to $26. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 41 straight weeks.
Today the stock is in a confirmed uptrend — week 17 of stage 2. At $24.4 it trades +107.9% versus its 200-day average and sits at 91% of its 52-week range ($3–$26).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved −98% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 41 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
P/E does not price ChronoScale Holdings Corporation — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values ChronoScale Holdings Corporation at 400.0× its FY25 revenue of $0.0 B.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
ChronoScale Holdings Corporation reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 8 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −66.7% | — | — | — |
| Stock price | +600.6% | +12.3% | −20.2% | −33.3% |
4-Factor Sector Score
50.0/100 — rank 11 of 27 in Information Technology Services · 64% evidence confidence
ChronoScale Holdings Corporation scores 50.0 out of 100 against the 27 companies it is compared with in Information Technology Services, ranking 11. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 20 + 3.7 + 11.5 + 14.8 = 50. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
ChronoScale Holdings Corporation reported $0.0 B of revenue in the Mar 26 quarter. Over 2 years it has compounded at −29.3% a year. The last full year, FY25, came in at $0.0 B. The last four reported quarters add to $−0.0 B.
FY25 revenue came in at $0.0 B (−87.5% on the year), capping 2 years at −29.3% compound. The latest quarter (Mar 26) printed $0.0 B, null year on year.
Pace check: the last four quarters averaged −350.0% growth against the decade's −29.3% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
A clean operating margin is not in our numbers for ChronoScale Holdings Corporation — its accounts do not report the operating-profit line this section reads, which is common for lenders and holding companies. The sections above and below carry the readings this company's filings do support.
This company's accounts do not report the operating-profit line this section reads — common for lenders and holding companies classified outside the financial bucket. The revenue and net-profit sections are the cleaner reads for ChronoScale Holdings Corporation.
🚨 Why the margin moved: operating margin went −50.0 pp year on year while gross margin went +0.0 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
ChronoScale Holdings Corporation posted a net loss of $0.01 B in the Mar 26 quarter. The full FY25 year was a loss of $0.01 B. The same quarter a year earlier earned $0.0 B. 5 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $−0.0 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
ChronoScale Holdings Corporation's cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $−0.0 B of operating cash against $−0.0 B of profit. After $0.0 B of capital spending, $−0.0 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $−0.0 B against reported profit of $−0.0 B, leaving free cash of $−0.0 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
ChronoScale Holdings Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
ChronoScale Holdings Corporation earns a ROE of −100% in FY25. That is up from a trough of −200% in FY23. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is −100.0% net margin on 0.50× asset turns.
FY25 ROE is −100%, recovered from a FY23 trough of −200% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): −100.0% net margin × 0.50× asset turns × 2.00× balance-sheet leverage ≈ −100.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
Dividend
ChronoScale Holdings Corporation pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
ChronoScale Holdings Corporation does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
ChronoScale Holdings Corporation carries total debt of $0.0 B against shareholder equity of $0.0 B as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.00 in FY21 to 0.00 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.0 B against shareholder equity of $0.0 B — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.00 (FY21) to 0.00 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
45.5% of ChronoScale Holdings Corporation's tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 2.9 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 45.5% of the float is sold short, and at typical trading volumes it would take about 2.9 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
ChronoScale Holdings Corporation: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Science Applications International CorporationSAIC | 67.6/100Favorable setup85% evidence | BREAKING OUT | 21.5/35 Revenue -2.9% · PAT 14.7% · OPM change 3 pp 95% evidence | 12.6/25 ROCE 4.5% · OPM 9.4% 76% evidence | 15.7/20 P/E 10.8× · PEG 0.44 65% evidence | 17.8/20 RS sector 8.2% · RS bench 6% · 1Y 3.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 12.6 + 15.7 + 17.8 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Jack Henry & Associates, Inc.JKHY | 59.6/100Mixed-positive evidence81% evidence | TURNING | 21.6/35 Revenue 8.4% · PAT 21.2% · OPM change 0.7 pp 83% evidence | 16.1/25 ROCE 6% · OPM 24.4% 76% evidence | 11.7/20 P/E 22.1× · PEG 1.01 65% evidence | 10.2/20 RS sector -9.5% · RS bench -11.8% · 1Y -3.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 16.1 + 11.7 + 10.2 = 59.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Broadridge Financial Solutions, Inc.BR | 58.8/100Mixed-positive evidence81% evidence | TURNING | 20.4/35 Revenue 8.2% · PAT 39.6% · OPM change -0.6 pp 83% evidence | 15.4/25 ROCE 5.2% · OPM 18.4% 76% evidence | 14.8/20 P/E 17.4× · PEG 0.43 65% evidence | 8.2/20 RS sector -20.2% · RS bench -22.8% · 1Y -36.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 15.4 + 14.8 + 8.2 = 58.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Gartner, Inc.IT | 57.8/100Mixed-positive evidence81% evidence | TURNING | 16.2/35 Revenue 2.3% · PAT -41% · OPM change 2.8 pp 83% evidence | 16.9/25 ROCE 7.5% · OPM 20.9% 76% evidence | 14.3/20 P/E 15.6× · PEG 0.45 65% evidence | 10.4/20 RS sector -12.3% · RS bench -15.3% · 1Y -18.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 16.9 + 14.3 + 10.4 = 57.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Penguin Solutions, Inc.PENG | 57.7/100Mixed-positive evidence67% evidence | LEADER | 24.6/35 Revenue 12% · PAT — · OPM change 7.6 pp 71% evidence | 10.2/25 ROCE 4.2% · OPM 10.6% 76% evidence | 8.6/20 P/E 39.6× · PEG — 15% evidence | 14.3/20 RS sector 67% · RS bench 67.3% · 1Y 148.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 10.2 + 8.6 + 14.3 = 57.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Innodata Inc.INOD | 56.2/100Mixed-positive evidence81% evidence | FADING | 24.0/35 Revenue 40.1% · PAT 11.4% · OPM change 4.6 pp 83% evidence | 16.4/25 ROCE 14.9% · OPM 18.8% 76% evidence | 3.9/20 P/E 34.8× · PEG 5.17 65% evidence | 11.9/20 RS sector 5.5% · RS bench 3.2% · 1Y 61.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 16.4 + 3.9 + 11.9 = 56.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 7ExlService Holdings, Inc.EXLS | 55.3/100Thin evidence · provisional58% evidence | TURNING | 19.2/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 15.9/25 ROCE 7% · OPM 16.1% 76% evidence | 9.9/20 P/E 16.3× · PEG — 15% evidence | 10.3/20 RS sector -11.1% · RS bench -13.9% · 1Y -18.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 15.9 + 9.9 + 10.3 = 55.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Ingram Micro Holding CorporationINGM | 53.6/100Thin evidence · provisional58% evidence | TURNING | 18.9/35 Revenue — · PAT — · OPM change 0 pp 45% evidence | 10.4/25 ROCE 3.1% · OPM 1.6% 76% evidence | 10.3/20 P/E 15× · PEG — 15% evidence | 14.0/20 RS sector 12.6% · RS bench 10.9% · 1Y 55.8%6 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 10.4 + 10.3 + 14 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9CGI Inc.GIB | 51.2/100Thin evidence · provisional58% evidence | TURNING | 17.9/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 13.2/25 ROCE 4.3% · OPM 14.9% 76% evidence | 11.0/20 P/E 11.4× · PEG — 15% evidence | 9.1/20 RS sector -14.7% · RS bench -17.2% · 1Y -22.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 13.2 + 11 + 9.1 = 51.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Genpact LimitedG | 50.8/100Mixed-positive evidence81% evidence | TURNING | 15.1/35 Revenue 6.4% · PAT 8% · OPM change 0.2 pp 83% evidence | 14.2/25 ROCE 4.8% · OPM 15.3% 76% evidence | 13.1/20 P/E 11.4× · PEG 1.01 65% evidence | 8.4/20 RS sector -15.7% · RS bench -18.2% · 1Y -17.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 14.2 + 13.1 + 8.4 = 50.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11ChronoScale Holdings Corporationthis pageCHRN | 50.0/100Mixed-positive evidence64% evidence | LEADER | 20.0/35 Revenue -164.9% · PAT — · OPM change 55.9 pp 62% evidence | 3.7/25 ROCE -112.9% · OPM -58.5% 76% evidence | 11.5/20 P/E 1× · PEG — 15% evidence | 14.8/20 RS sector 110.7% · RS bench 112.4% · 1Y 717.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 3.7 + 11.5 + 14.8 = 50 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Cognizant Technology Solutions CorporationCTSH | 48.8/100Thin evidence · provisional58% evidence | TURNING | 15.6/35 Revenue — · PAT — · OPM change -1.1 pp 45% evidence | 14.6/25 ROCE 5.1% · OPM 15.6% 76% evidence | 11.4/20 P/E 8.3× · PEG — 15% evidence | 7.2/20 RS sector -20.3% · RS bench -22.9% · 1Y -19.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 14.6 + 11.4 + 7.2 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13CDW CorporationCDW | 46.9/100Mixed-negative evidence81% evidence | TURNING | 13.9/35 Revenue 7.4% · PAT -0.8% · OPM change -0.4 pp 83% evidence | 11.3/25 ROCE 4.2% · OPM 6.6% 76% evidence | 6.0/20 P/E 14.7× · PEG 4.79 65% evidence | 15.7/20 RS sector 2.2% · RS bench -0.3% · 1Y -5.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 11.3 + 6 + 15.7 = 46.9 · Decision use: Price leads the evidence: RS versus the benchmark is -0.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 14CACI International IncCACI | 45.9/100Mixed-negative evidence81% evidence | TURNING | 18.0/35 Revenue 9.6% · PAT 12.6% · OPM change 0.6 pp 83% evidence | 10.6/25 ROCE 2.6% · OPM 9.7% 76% evidence | 9.3/20 P/E 22.4× · PEG 1.56 65% evidence | 8.0/20 RS sector -11.3% · RS bench -13.4% · 1Y 5.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 10.6 + 9.3 + 8 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Leidos Holdings, Inc.LDOS | 44.5/100Mixed-negative evidence68% evidence | BASING | 13.5/35 Revenue — · PAT — · OPM change -1 pp 45% evidence | 12.1/25 ROCE 4.5% · OPM 11.5% 76% evidence | 14.5/20 P/E 14.5× · PEG 0.52 65% evidence | 4.4/20 RS sector -26.5% · RS bench -28.8% · 1Y -26%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.5 + 12.1 + 14.5 + 4.4 = 44.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 16Cipher Digital Inc.CIFR | 43.3/100Mixed-negative evidence64% evidence | FADING | 17.5/35 Revenue 38.8% · PAT — · OPM change -251.1 pp 62% evidence | 4.2/25 ROCE -3.9% · OPM -328.9% 76% evidence | 8.5/20 P/E 83× · PEG — 15% evidence | 13.1/20 RS sector 10% · RS bench 8.2% · 1Y 329.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 4.2 + 8.5 + 13.1 = 43.3 · Decision use: Price leads the evidence: RS versus the benchmark is 8.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 17EPAM Systems, Inc.EPAM | 41.9/100Mixed-negative evidence81% evidence | TURNING | 18.6/35 Revenue 14.2% · PAT -5.8% · OPM change 0.7 pp 83% evidence | 10.8/25 ROCE 3% · OPM 8.3% 76% evidence | 6.4/20 P/E 19.4× · PEG 2.74 65% evidence | 6.1/20 RS sector -29.6% · RS bench -32.2% · 1Y -29.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 10.8 + 6.4 + 6.1 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18International Business Machines CorporationIBM | 40.3/100Thin evidence · provisional58% evidence | ASLEEP | 16.4/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence | 9.8/25 ROCE 2.6% · OPM 11.7% 76% evidence | 9.0/20 P/E 25× · PEG — 15% evidence | 5.1/20 RS sector -19.4% · RS bench -21.5% · 1Y -2.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 9.8 + 9 + 5.1 = 40.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Fidelity National Information Services, Inc.FIS | 39.8/100Mixed-negative evidence71% evidence | BASING | 12.7/35 Revenue 12.3% · PAT -257.8% · OPM change -0.9 pp 83% evidence | 9.4/25 ROCE 1.4% · OPM 12.8% 76% evidence | 11.2/20 P/E 9.1× · PEG — 15% evidence | 6.5/20 RS sector -25.9% · RS bench -28.3% · 1Y -37.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 9.4 + 11.2 + 6.5 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Keel Infrastructure Corp.KEEL | 39.8/100Mixed-negative evidence64% evidence | FADING | 12.9/35 Revenue 51.6% · PAT — · OPM change -192.9 pp 62% evidence | 3.9/25 ROCE -11.6% · OPM -266% 76% evidence | 9.5/20 P/E 20.8× · PEG — 15% evidence | 13.5/20 RS sector 17.7% · RS bench 15.9% · 1Y 231.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 3.9 + 9.5 + 13.5 = 39.8 · Decision use: Price leads the evidence: RS versus the benchmark is 15.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21Pony AI Inc.PONY | 39.8/100Mixed-negative evidence61% evidence | BASING | 24.6/35 Revenue 41.6% · PAT — · OPM change 230.6 pp 62% evidence | 4.0/25 ROCE -4.5% · OPM -170.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.2/20 RS sector -42.4% · RS bench -44.7% · 1Y -45.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 4 + 10 + 1.2 = 39.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -42.4% and the one-year return is -45.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 22Accenture plcACN | 39.2/100Mixed-negative evidence85% evidence | BASING | 12.2/35 Revenue 6.7% · PAT -2% · OPM change 0.2 pp 95% evidence | 15.8/25 ROCE 6.9% · OPM 17% 76% evidence | 6.3/20 P/E 14.9× · PEG 3.4 65% evidence | 4.9/20 RS sector -27.5% · RS bench -29.9% · 1Y -28.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.2 + 15.8 + 6.3 + 4.9 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Applied Digital CorporationAPLD | 37.6/100Thin evidence · provisional55% evidence | FADING | 16.7/35 Revenue — · PAT — · OPM change -31.8 pp 45% evidence | 4.5/25 ROCE -2.5% · OPM -67.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.4/20 RS sector -4.6% · RS bench -6.4% · 1Y 120.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 4.5 + 10 + 6.4 = 37.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24Kyndryl Holdings, Inc.KD | 35.2/100Mixed-negative evidence71% evidence | TURNING | 11.9/35 Revenue 0.2% · PAT -21.4% · OPM change 0.6 pp 83% evidence | 7.1/25 ROCE 2.6% · OPM 4.3% 76% evidence | 10.2/20 P/E 15.4× · PEG — 15% evidence | 6.0/20 RS sector -32.4% · RS bench -35.3% · 1Y -52.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 7.1 + 10.2 + 6 = 35.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Parsons CorporationPSN | 34.8/100Thin evidence · provisional58% evidence | BASING | 13.9/35 Revenue — · PAT — · OPM change -0.6 pp 45% evidence | 9.0/25 ROCE 0.1% · OPM 6.4% 76% evidence | 8.8/20 P/E 36.1× · PEG — 15% evidence | 3.1/20 RS sector -32.2% · RS bench -34.2% · 1Y -37.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 9 + 8.8 + 3.1 = 34.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Wise Group plcWSE | 43.6/100Thin evidence · provisional49% evidence | ASLEEP | 16.2/35 Revenue — · PAT — · OPM change -7.3 pp 19% evidence | 11.7/25 ROCE 0% · OPM 30.1% 76% evidence | 9.2/20 P/E 24.6× · PEG — 15% evidence | 6.5/20 RS sector -10.7% · RS bench -12.5% · 1Y -10.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 11.7 + 9.2 + 6.5 = 43.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27NIQ Global Intelligence plcNIQ | 37.5/100Thin evidence · provisional47% evidence | TURNING | 16.1/35 Revenue — · PAT — · OPM change -2.6 pp 39% evidence | 4.9/25 ROCE -0.4% · OPM -1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.5/20 RS sector -17.6% · RS bench -20.3% · 1Y -34.8%0 of 12 weeks ahead 70% evidence |
| Exact sum: 16.1 + 4.9 + 10 + 6.5 = 37.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is ChronoScale Holdings Corporation's stock price today?
ChronoScale Holdings Corporation trades at $24.4, +600.6% over the past year. The company is valued at $4.0 B. The stock sits at 91% of its 52-week range of $3–$26, +107.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 17 weeks in. — as of 5 August 2026.
What were ChronoScale Holdings Corporation's latest quarterly results?
ChronoScale Holdings Corporation reported revenue of $0.0 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−2.04. — as of 5 August 2026.
What is ChronoScale Holdings Corporation's revenue?
ChronoScale Holdings Corporation reported revenue of $0.0 B in the Mar 26 quarter. For the full FY25 fiscal year, revenue was $0.0 B (−87.5%). Over the last 2 years revenue compounded at −29.3% a year. — as of 5 August 2026.
What is ChronoScale Holdings Corporation's profit?
ChronoScale Holdings Corporation earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.0 B. — as of 5 August 2026.
What is ChronoScale Holdings Corporation's market cap?
ChronoScale Holdings Corporation's market capitalisation is $4.0 B at a stock price of $24.4. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does ChronoScale Holdings Corporation pay a dividend?
No — ChronoScale Holdings Corporation has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
How is ChronoScale Holdings Corporation performing?
ChronoScale Holdings Corporation is in a confirmed uptrend, 17 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 41 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is ChronoScale Holdings Corporation in an uptrend?
Yes — the price is in a confirmed uptrend (week 17 of stage 2), trading +107.9% versus its 200-day average and at 91% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is ChronoScale Holdings Corporation beating the market?
On recent form, yes — ChronoScale Holdings Corporation has been ahead of the S&P 500 on a trailing-13-week view for 41 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved −98% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will ChronoScale Holdings Corporation's stock price go up?
This page publishes no price forecast for ChronoScale Holdings Corporation. What it measures instead: the stock price is $24.4, the price is in a confirmed uptrend 17 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against ChronoScale Holdings Corporation?
Yes — short interest is 45.5% of ChronoScale Holdings Corporation's tradable float, about 2.9 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does ChronoScale Holdings Corporation have too much debt?
It carries real leverage — ChronoScale Holdings Corporation's debt-to-equity is 1.43. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is ChronoScale Holdings Corporation's capex?
ChronoScale Holdings Corporation spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is ChronoScale Holdings Corporation's cash flow?
ChronoScale Holdings Corporation generated $−0.0 B of operating cash flow in FY25 and $−0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $−0.0 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Where is ChronoScale Holdings Corporation in its business cycle?
ChronoScale Holdings Corporation's FY25 operating margin was −100.0%, against a 5-year band of −233.3%–−50.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the ChronoScale Holdings Corporation story?
Biggest watch item: the price is already 17 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is ChronoScale Holdings Corporation a stock worth studying right now?
This is not investment advice. The machine read: ChronoScale Holdings Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.